Scope of the PIP in the EU: easier accessibility to the paediatric rewards and simplification of administrative requirements
This article was originally published in SRA
The European Medicines Agency’s policy on changes in the scope of paediatric investigation plan decisions will make it easier for drug companies to reap the available rewards as well as cut down on the paperwork, insist Paolo Tomasi and Agnes Saint Raymond.
You may also be interested in...
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.